Spero Therapeutics (NASDAQ:SPRO) Receives Hold Rating from TD Cowen

Spero Therapeutics (NASDAQ:SPRO)‘s stock had its “hold” rating reaffirmed by analysts at TD Cowen in a research note issued to investors on Monday,Benzinga reports.

Several other research firms have also recently weighed in on SPRO. HC Wainwright cut their price objective on Spero Therapeutics from $7.00 to $5.00 and set a “buy” rating on the stock in a report on Monday, November 4th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Spero Therapeutics in a report on Friday.

Spero Therapeutics Price Performance

NASDAQ:SPRO opened at $1.19 on Monday. Spero Therapeutics has a fifty-two week low of $1.01 and a fifty-two week high of $1.89. The stock has a market capitalization of $64.24 million, a PE ratio of 17.00 and a beta of 0.63. The business’s 50-day simple moving average is $1.29 and its 200-day simple moving average is $1.36.

Institutional Investors Weigh In On Spero Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Virtu Financial LLC acquired a new stake in Spero Therapeutics in the 1st quarter valued at approximately $31,000. Renaissance Technologies LLC raised its position in Spero Therapeutics by 14.2% in the 2nd quarter. Renaissance Technologies LLC now owns 975,952 shares of the company’s stock valued at $1,269,000 after buying an additional 121,492 shares during the last quarter. Acadian Asset Management LLC raised its position in Spero Therapeutics by 121.8% in the 1st quarter. Acadian Asset Management LLC now owns 762,598 shares of the company’s stock valued at $1,310,000 after buying an additional 418,742 shares during the last quarter. Murchinson Ltd. raised its position in Spero Therapeutics by 1.3% in the 1st quarter. Murchinson Ltd. now owns 873,910 shares of the company’s stock valued at $1,503,000 after buying an additional 11,210 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in Spero Therapeutics by 0.6% in the 1st quarter. Vanguard Group Inc. now owns 1,653,432 shares of the company’s stock valued at $2,844,000 after buying an additional 9,675 shares during the last quarter. Institutional investors and hedge funds own 25.60% of the company’s stock.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.